From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
|Articles|June 1, 2001
Bexarotene safe treatment for early-stage CTCL
Washington - Bexarotene gel appears to be an effective and well-tolerated monotherapy when used as first-line treatment for early-stage cutaneous T-cell lymphoma, Madeleine Duvic, M.D., reported at the annual meeting of the American Academy of Dermatology.
Advertisement
Advertisement
Related to this article
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
Explore trending plant oils in skincare and haircare, plus 2026’s hottest actives like ectoin and hypochlorous acid—balancing glow, barrier repair, and irritation risks.
Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
4
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
5